Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2021

Conditions
Hidradenitis Suppurativa
Interventions
DEVICE

Laight therapy, NICE V3.1 device

Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.

Trial Locations (1)

48202

Henry Ford Hospital Systems- New Center One, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT05927948 - Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter